U.S. markets open in 9 minutes

American CryoStem Corporation (CRYO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2699+0.0040 (+1.52%)
At close: 1:04PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2659
Bid0.1050 x 5000
Ask1.5000 x 500
Day's Range0.2500 - 0.2699
52 Week Range0.1600 - 1.1800
Avg. Volume24,434
Market Cap16.419M
Beta (5Y Monthly)-0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more

    American CryoStem Executes LOI with Advanced Regenerative Associates to Conduct Wound Healing Clinical Study

    Advanced Regenerative Associates, led by Dr. DeMarco, is dedicated to developing a line of cellular therapy products and devices to treat and mitigate the effects of diabetic wounds and skin ulcers for patients not responding to current standards of care.


    American CryoStem Announces Patient Biomaterial Processing for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial

    EATONTOWN, NJ / ACCESSWIRE / March 11, 2021 / American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has begun processing patient's adipose tissue and culturing mesenchymal stem cells (ATCell™), for use in its FDA approved IND Phase I Clinical Trial.The Company's autologous mesenchymal stem cell infusion therapy ("Investigational Drug") development is part of a single center study under the protocol entitled: ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post-Concussion Syndrome (PCS) in Retired Military and Athletes.


    American CryoStem and BioTherapeutic Labs Corp. Enter into R&D, Collaboration and Marketing Agreement

    EATONTOWN, NJ / ACCESSWIRE / February 25, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies, announced today that it has entered into an Agreement with BioTherapeutic Labs Corp. (BTL) an FDA registered Umbilical Cord Tissue Manufacturing Company headquartered in Boca Raton, Florida.